title: Amantadine-induced myoclonus in a patient with progressive supranuclear palsy.
abstract: Progressive supranuclear palsy (PSP) is a tauopathy that generally results in a hypokinetic disorder. Treatment is largely symptomatic, with some small studies indicating a benefit with dopaminergic therapy. Myoclonus is a hyperkinetic disorder that can be seen as part of later stage Parkinson's disease and in multiple system atrophy, but is rarely seen in PSP. Here we report a case of myoclonus precipitated by amantadine in a patient with PSP.
authors.affiliation: Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK. alison.yarnall@ncl.ac.uk
authors.forename: Alison Jane
authors.initials: AJ
authors.lastname: Yarnall
authors.forename: David John
authors.initials: DJ
authors.lastname: Burn
mesh_terms: D000368:Aged; D000547:Amantadine / Q000009:adverse effects* / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009207:Myoclonus / Q000139:chemically induced* / Q000175:diagnosis; D013494:Supranuclear Palsy, Progressive / Q000188:drug therapy*; D016896:Treatment Outcome; D028761:Withholding Treatment
chemical_list: D015259:Dopamine Agents; D000547:Amantadine